Robert Coffman, Chief Scientific Officer & VP at DYNAVAX TECHNOLOGIES CORP (DVAX), sold 8,000 shares at $4.52 ($36K) on 2012-09-13, disclosed to the SEC on 2012-09-14.
Scheduled sale ($36k) by Chief Scientific Officer & VP under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| DVAX | SELL | 2017-12-15 | $142K | — | Filing → |
| DVAX | SELL | 2012-11-07 | $34K | — | Filing → |
| DVAX | SELL | 2012-10-09 | $40K | — | Filing → |